The solution for clinical trials combines Entra Health’s MyGlucoHealth Wireless blood glucose meter with PHT’s ePRO System to create an automated glucose monitoring and ePRO solution.
The integration between PHT’s handheld technology and the MyGlucoHealth’s Wireless glucometer is expected to provide ease of use for patients while improving data flow and ensuring participation and compliance.
Richard Strobridge, CEO of Entra Health Systems, said: “It comes down to hard data versus soft data. Clinical Investigators now have direct access to real-time blood glucose data during clinical trials. Patient-related inaccuracies are eliminated.
“With the MyGlucoHealth Wireless meter we can monitor in real-time not just blood glucose readings, but when and how often patients are testing. Also, MyGlucoHealth offers a higher level of accuracy along with the unique ability to wirelessly upload readings using Bluetooth.”
Phil Lee, president and CEO of PHT, said: “Our goal in launching this solution is to capture time-sensitive data, directly from the patient. Research studies have shown hand-written paper log book entries of glucose data contain numerous errors both in transcription and time accuracy.
“Waiting, downloading, or transcribing this critical data lead to delays and poor clinical trial data quality. Sponsors demand the most accurate real-time data to monitor patient status and evaluate compliance and study effectiveness. The PHT and MyGlucoHealth partnership brings a new level of sophistication to clinical trials that capture blood glucose information.”